22UA:FRA
BioNTech SE - ADR
€85.65
arrow_downward
-0.23%(-0.20) 1D
Oct 1, 10:16:45 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€87.75
High
€87.75
Low
€85.60
Mkt. cap
24.69B
Avg. vol.
1.13K
Volume
91.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
Open
€87.75
High
€87.75
Low
€85.60
Mkt. cap
24.69B
Avg. vol.
1.13K
Volume
91.00
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
BioNTech's Founders Are Building a New mRNA Company While Their Old One Shrinks to a Cancer Lab
Stock Titan
·
13 hours ago
Under a June 3 trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 34,000 and 32,000 shares.
TipRanks
·
17 hours ago
BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial
AD HOC NEWS
·
18 hours ago
BioNTech stock trades at EUR 86.05 after a revenue miss
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR